Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668414 · ClinicalTrials.gov registry record · Phase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
NCT07668414: Clinical Trial Phase 3 study, sponsored by Novo Nordisk A/S.
NCT07668414 is a Phase 3 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 650 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07668414, a Phase 3 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Primary Outcome
Measured as percentage (%) change in body weight.
Interventions
- DRUG Semaglutide
- DRUG Zenagamtide
- DRUG Placebo (matched to semaglutide)
- DRUG Placebo (matched to zenagamtide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2026-09-22 |
| Est. Completion | 2028-10-10 |
| Phase | Phase 3 |
What is known before NCT07668414 opens enrollment
NCT07668414 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT07668414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07668414 about?
NCT07668414 is a clinical study titled "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide". The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
What is the current status of trial NCT07668414?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2026-09-22. Estimated completion is 2028-10-10.
What interventions are being tested in trial NCT07668414?
The interventions under investigation include: Semaglutide (DRUG), Zenagamtide (DRUG), Placebo (matched to semaglutide) (DRUG), Placebo (matched to zenagamtide) (DRUG).
Who is sponsoring clinical trial NCT07668414?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07668414's enrollment target sits among peer trials
650 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI